10x Genomics, Inc. (TXG): restructuring charge — 10x Genomics revenue ex-settlement falls 2% YoY; cuts 8% workforce, withdraws FY guidance

10x Genomics, Inc.

2025-Q1 EPS reported -$0.28 revenue$154,883,000

Q1 revenue $154.9M incl $16.8M patent settlement; ex-settlement $138.1M, down 2% YoY.
Net loss $34.4M vs $59.9M YoY; operating loss $39.3M, improved from $61.5M.
Cutting ~8% of global workforce; expects $5.5-6.5M severance in Q2 2025.
Withdraws full-year 2025 guidance citing US academic/government funding uncertainty.
Q2 2025 revenue guidance $138-142M (ex-settlement), 1% sequential growth at midpoint.

item 2.02 item 2.05 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Restructurings & Charges SEC 8-K Item 2.05/2.06 confidence 0.9

10x Genomics, Inc. announced a restructuring with charges of between $5.5 million and $6.5 million (approximately 8% of the Company’s global workforce).

Type: restructuring
Charge: between $5.5 million and $6.5 million
Headcount: approximately 8% of the Company’s global workforce

Exact text from the filing

On May 6, 2025, to decrease its costs and adjust its organizational structure to align with its strategic priorities, the Company committed to a reduction in force that is expected to result in the termination of approximately 8% of the Company’s global workforce. In connection with the reduction in force, the Company currently estimates it will incur between $5.5 million and $6.5 million of costs consisting primarily of cash severance costs which the Company expects to recognize in the second quarter of 2025 and pay by the end of third quarter of 2025.

View on SEC.gov

20 restructurings & charges filed in the last 30 days. Browse all restructurings & charges →

10x Genomics, Inc. filing history →

Source: SEC EDGAR

accession 0001770787-25-000031

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.